Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
11 mars 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
10 mars 2020 07h05 HE
|
Precision Biosciences
-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3
24 févr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
13 janv. 2020 07h00 HE
|
Precision Biosciences
-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A...
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
12 nov. 2019 07h15 HE
|
Precision Biosciences
DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
06 nov. 2019 09h01 HE
|
Precision Biosciences
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- ...
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
08 août 2019 07h49 HE
|
Autolus Therapeutics plc
LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
02 août 2019 09h06 HE
|
Autolus Therapeutics plc
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
26 mars 2019 06h00 HE
|
Autolus Therapeutics plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...
Title21 Health Solutions® to Showcase its BMT Software Solution 8.5 at the 2018 BMT Tandem Meeting
30 nov. 2017 12h00 HE
|
Title21 Health Solutions, Inc.
PLEASANTON, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Title21 Health Solutions, “Title21”, an innovator of integrated enterprise software for blood and marrow transplant programs supporting...